Initiate a Phase 3 study of simufilam in Alzheimer's disease
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 8 Feb 2021
- Due
- 31 Dec 2021
- Delivered
- 6 Oct 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“We plan to initiate a Phase 3 study of simufilam in Alzheimer's disease in 2nd half 2021.”
What we found
Evidence strength A What the grades mean
The company initiated its two Phase 3 studies of simufilam in October and November 2021, meeting the commitment to begin the program in the second half of 2021.
-
A Cassava Sciences Inc. 10-K filed 2022-03-01
“On October 6, 2021, and November 18, 2021, we announced initiation of our two Phase 3 studies of simufilam, respectively.” ✓ confirmed on the page
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Phase 3 study of simufilam
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- Medium
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Cassava Sciences Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-FLNA-023239 · Corrections policy